白。在此,我们将简述QLQ.BM22量表的发展过程,应用优势及信效 度检测。 1简 介 EORTCQLQ.BM22(表1口)即欧洲癌症研究与治疗组织的生活 质量骨转移量表,用于骨转移患者生活质量的评测。往往与EORTC 严重失衡,形成了特殊的人际关系和人际沟通问题。很多学生反映, ...
EORTC QLQ-BM22
[结论]中国本土化的EORTC QLQBM22具有可靠性、有效性和可接受性,可用于评价中国癌症骨转移病人的生活质量。罗志芹焦杰陈佳悦林允寿吴美静张曼钰孙伟林张雷护理研究:中旬版EORTC QLQ-BM22在评价中国癌症骨转移病人生活质量中的有效性研究[J]. 罗志芹,焦杰,陈佳悦,林允寿,吴美静,张曼钰,孙伟林,张雷.护理研究. 2015...
Pearson相关检验及Wilcoxon秩和检验进行统计分析.[结果]4个领域的内部一致性均得到确认;EORTC QLQ-BM22与EORTCQLQ-C30之间具有足够的相关性,但二者存在一定差异;4个领域在不同KPS分组(KPS≤80;KPS〉80)中的差异有统计学意义(P〈0.05);量表依从性较高.[结论]中国本土化的EORTC QLQBM22具有可靠性,有效性和可接受...
EORTC QLQ-BM22 介绍及发展 陈佳悦;张雷 【期刊名称】《中国医药指南》 【年(卷),期】2014(000)026 【摘要】 EORTC QLQ-BM22 ( Europe Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Bone Metastases22) 即欧洲癌症研究与治疗组织的生活质量骨转移量表,目前已在不同国家被...
The IN-PATSAT32 and QLQ-INFO25 are questionnaires which can be applied to assess and improve communication with cancer patients, as well as for research and clinical trials aimed at assessing patients’ satisfaction and perception of the information rece
Understanding the EORTC QLQ-BM22, the module for patients with bone metastases. the European Organization for Research and Treatment of Cancer (EORTC) QoL Group Bone Metastases Module (QLQ-BM22) according to the module development ... E Chow,A Bottomley - 《Expert Review of Pharmacoeconomics &...
A brief supplementary instrument named WISP (Write In three Symptoms/Problems) was developed in Denmark for use alongside the QLQ-C15-PAL. This is an open-ended question allowing patients to report and rate the severity of up to three additional symptoms/problems not included in the QLQ-C15-PA...
[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Japanese patients with bone metastases--The Japanese version of the EORTC QLQ-BM22] Satoh T; Kobayashi K; Hori T;.The European Organisationfor Research and Treatment of Cancer (EORTC) ...
(NR vs. 23.5 months; HR 0.63, 95% CI, 0.45–0.88), Fig.4. Quality of life was also significantly improved in the immunotherapy arm using the EORTC QLQ -C30 scale [41]. OS, the second co-primary outcome, are expected in 2021. These results confirm pembrolizumab as standard of care, ...